Are the particular good times over for late-stage valuations? Not yet. Read More
Related Articles
What comes next after the Biogen Alzheimer’s drug approval
Biogen’s Alzheimer’s drug approval could pave the way for major changes across the industry. Read More
Wall Street shakes off bad jobs report, gets Biden stimulus boost
Good evening, Bull Sheeters. This is Fortune finance reporter Rey Mashayekhi, filling in for Bernhard with a special PM edition of the newsletter. It’s been a long, eventful week, to say the least—but an altogether good one for markets globally, which head into the weekend on a mostly positive note. Let’s get into the day’s […]
The cashless economy: How fintech is approaching the future of finance
Subscribe to The Ledger for expert weekly analysis on fintech’s big stories, delivered free to your inbox. Cashless payments were on the rise before the pandemic hit, and now, eight months into its grip on the U.S., their use is accelerating even faster. This was the topic of conversation at Fortune’s latest Brainstorm Finance panel […]